- Home
- BAX vs EXEL Comparison
BAX vs EXEL Comparison
Compare BAX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAX
- EXEL
- Stock Information
- Founded
- BAX 1931
- EXEL 1994
- Country
- BAX United States
- EXEL United States
- Employees
- BAX N/A
- EXEL N/A
- Industry
- BAX Medical/Dental Instruments
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAX Health Care
- EXEL Health Care
- Exchange
- BAX Nasdaq
- EXEL Nasdaq
- Market Cap
- BAX 11.3B
- EXEL 10.4B
- IPO Year
- BAX N/A
- EXEL 2000
- Fundamental
- Price
- BAX $22.04
- EXEL $38.50
- Analyst Decision
- BAX Hold
- EXEL Buy
- Analyst Count
- BAX 9
- EXEL 22
- Target Price
- BAX $30.78
- EXEL $44.00
- AVG Volume (30 Days)
- BAX 6.1M
- EXEL 2.4M
- Earning Date
- BAX 11-07-2025
- EXEL 10-28-2025
- Dividend Yield
- BAX 3.08%
- EXEL N/A
- EPS Growth
- BAX N/A
- EXEL 81.76
- EPS
- BAX N/A
- EXEL 2.08
- Revenue
- BAX $10,887,000,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- BAX $7.39
- EXEL $9.10
- Revenue Next Year
- BAX $3.79
- EXEL $12.47
- P/E Ratio
- BAX N/A
- EXEL $18.51
- Revenue Growth
- BAX 3.60
- EXEL 10.73
- 52 Week Low
- BAX $21.33
- EXEL $26.06
- 52 Week High
- BAX $37.74
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- BAX 38.23
- EXEL 43.94
- Support Level
- BAX $21.63
- EXEL $38.35
- Resistance Level
- BAX $23.04
- EXEL $41.44
- Average True Range (ATR)
- BAX 0.65
- EXEL 1.03
- MACD
- BAX 0.00
- EXEL -0.25
- Stochastic Oscillator
- BAX 16.82
- EXEL 23.17
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.